• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of bullwhoWHO Home PageBulletin Home PageBulletin Home PageAbout Bulletine-mail AlertSubmissions
Bull World Health Organ. Feb 2009; 87(2): 123–129.
Published online Jan 6, 2009. doi:  10.2471/BLT.08.051961
PMCID: PMC2636201

Language: English | French | Spanish | Arabic

Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania

Rapport coût/efficacité du traitement préventif intermittent contre le paludisme (TPI) chez le nourrisson au Mozambique et en République unie de Tanzanie

Costoeficacia del tratamiento preventivo intermitente (TPI) de la malaria en los lactantes (TPIL) en Mozambique y en la República Unida de Tanzanía

مردودية المعالجة الوقائية المتقطعة للملاريا لدى الرضع في موزمبيق و جمهورية تنزانيا المتحدة

Abstract

Objective

To estimate the cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP).

Methods

In two previous IPTi trials in Ifakara (United Republic of Tanzania) and Manhiça (Mozambique), SP was administered three times to infants before 9 months of age through the Expanded Programme on Immunization. Based on the efficacy results of the intervention and on malaria incidence in the target population, an estimate was made of the number of clinical malaria episodes prevented. This number and an assumed case-fatality rate of 1.57% were used, in turn, to estimate the number of disability-adjusted life years (DALY) averted and the number of deaths averted. The cost of the intervention, including start-up and recurrent costs, was then assessed on the basis of these figures.

Findings

The cost per clinical episode of malaria averted was US$ 1.57 (range: US$ 0.8–4.0) in Ifakara and US$ 4.73 (range: US$ 1.7–30.3) in Manhiça; the cost per DALY averted was US$ 3.7 (range: US$ 1.6–12.2) in Ifakara and US$ 11.2 (range: US$ 3.6–92.0) in Manhiça; and the cost per death averted was US$ 100.2 (range: US$ 43.0–330.9) in Ifakara and US$ 301.1 (range: US$ 95.6–2498.4) in Manhiça.

Conclusion

From the health system and societal perspectives, IPTi with SP is expected to produce health improvements in a cost-effective way. From an economic perspective, it offers good value for money for public health programmes.

Résumé

Objectif

Estimer le rapport coût/efficacité d’un traitement préventif intermittent contre le paludisme (TPI) à base de sulfadoxine-pyriméthamine (SP) chez le nourrisson.

Méthodes

Dans le cadre de deux essais antérieurs du TPI menés à Ifakara (République unie de Tanzanie) et à Manhiça (Mozambique), de la SP a été administrée à trois reprises à des nourrissons avant qu’ils atteignent 9 mois, par le biais du Programme élargi de vaccination. A partir des résultats d’efficacité de l’intervention et de l’incidence du paludisme dans la population cible, on a établi une estimation du nombre d’épisodes de paludisme clinique évités. On a utilisé à son tour ce nombre et un taux de létalité supposé de 1,57% pour estimer le nombre d’années de vie corrigées de l’incapacité (DALY) et le nombre de décès évités. Sur la base de ces chiffres, on a ensuite évalué le coût de l’intervention (y compris les coûts de lancement et les coûts récurrents).

Résultats

Le coût par épisode de paludisme clinique évité se montait à US $ 1,57 (plage de variation : US $ 0,8-4,0) à Ifakara et à US $ 4,73 (plage de variation : US $ 1,7-30,3) à Manhiça ; le coût par DALY évitée était de US $ 3,7 (plage de variation : US $ 1,6-12,2) à Ifakara et de US $ 11,2 (plage de variation : US $ 3,6-92,0) à Manhiça ; et le coût par décès évité atteignait US $ 100,2 (plage de variation : US $ 43,0-330,9) à Ifakara et US $ 301,1 (plage de variation : US $ 95,6-2498,4) à Manhiça.

Conclusion

Du point de vue du système de santé et de la société, on s’attend à ce qu’un TPI à base de SP apporte des améliorations sur le plan sanitaire avec un bon rapport coût/efficacité. Dans une perspective économique, ce traitement offre un bon retour sur investissement pour les programmes de santé publique.

Resumen

Objetivo

Estimar la costoeficacia del tratamiento preventivo intermitente (TPI) de la malaria en los lactantes con sulfadoxina-pirimetamina (SP).

Métodos

En dos ensayos previos de TPI en lactantes llevados a cabo en Ifakara (República Unida de Tanzanía) y Manhiça (Mozambique), se administró SP en tres ocasiones a lactantes de menos de 9 meses a través del Programa Ampliado de Inmunización. A partir de los resultados sobre la eficacia de la intervención y de la incidencia de malaria en la población objetivo, se estimó el número de episodios clínicos de la enfermedad prevenidos. Esa cifra, unida a una tasa de letalidad supuesta del 1,57%, se usó a su vez para estimar el número de años de vida ajustados en función de la discapacidad (AVAD) evitados y el número de muertes evitadas. Por último, sobre la base de esas cifras se determinaron los costos iniciales y los costos ordinarios.

Resultados

El costo por episodio clínico de malaria evitado fue de US$ 1,57 (intervalo: US$ 0,8–4,0) en Ifakara y de US$ 4,73 (intervalo: US$ 1,7–30,3) en Manhiça; el costo por DALY evitado fue de US$ 3,7 (intervalo: US$ 1,6–12,2) en Ifakara y de US$ 11,2 (intervalo: US$ 3,6–92,0) en Manhiça; y el costo por defunción evitada fue de US$ 100,2 (intervalo: US$ 43,0–330,9) en Ifakara y de US$ 301,1 (intervalo: US$ 95,6–2498,4) en Manhiça.

Conclusión

Desde el punto de vista del sistema de salud y de la sociedad, cabe deducir que el TPI en lactantes con SP redunda en mejoras sanitarias de forma costoeficaz. Desde una perspectiva económica, la medida supone una buena inversión para los programas de salud pública.

ملخص

الهدف

تقدير مردودية المعالجة الوقائية المتقطعة للملاريا لدى الرضع باستعمال السلفادوكسين - بيريميثامين.

الطريقة

في تجربتين سابقتين للمعالجة الوقائية المتقطعة للملاريا لدى الرضع، أجريتا في “إيفاكارا” (بجمهورية تنزانيا المتحدة)، و”مانهيسا” (بموزمبيق)، أعطيت السلفادوكسين – بيريميثامين ثلاث مرات للرضع، قبل بلوغهم الشهر التاسع من العمر، من خلال البرنامج الموسع للتمنيع. وبناء على نتائج فعالية المداخلة، ووقوعات الملاريا في المجموعة السكانية المستهدفة، تم تقدير عدد نوبات الملاريا السريرية التي أمكن توقيها. واستُخدم هذا العدد إلى جانب معدل مفترض لإماتة الحالات مقداره 1.57%، لتقدير عدد سنوات العمر المصححة باحتساب مدد العجز، التي أمكن تجنبها، وكذلك عدد الوفيات التي أمكن تفاديها. وقدرت تكاليف المداخلة، بما فيها تكاليف البدء الأولية والتكاليف المتكررة، بناء على هذه الأرقام.

الموجودات

بلغت تكلفة كل نوبة ملاريا سريرية أمكن توقيها 1.57 دولار أمريكي (المدى 0.8 – 4.0 دولار أمريكي) في “إيفاكارا”، و4.73 دولار أمريكي (المدى 1.7 – 30.3 دولار أمريكي) في “مانهيسا”. وبلغت تكلفة كل سنة من سنوات العمر المصححة باحتساب مدد العجز، أمكن تجنبها 3.7 دولار أمريكي (المدى 1.6 – 12.2 دولار أمريكي) في “إيفاكارا”، و11.2 دولار أمريكي (المدى 3.6 – 92.0 دولار أمريكي) في “مانهيسا”، وتكلفة كل وفاة أمكن تفاديها 100.2 دولار أمريكي (المدى 43.0 – 330.9 دولار أمريكي) في “إيفاكارا”، و301.1 دولار أمريكي (المدى 95.6 – 2498.4 دولار أمريكي) في “مانهيسا”.

الاستنتاج

يتوقع أن تؤدي المعالجة الوقائية المتقطعة للملاريا لدى الرضع باستعمال السلفادوكسين – بيريميثامين، إلى تحسن عالي المردود في الصحة وذلك من الناحية الصحية والاجتماعية. ومن الوجهة الاقتصادية فإنها تحقق لبرامج الصحة العمومية استفادة عظيمة القيمة من الأموال التي تنفق في هذا المجال.

Introduction

Malaria is one of the leading causes of morbidity in endemic countries. Between 350 and 660 million clinical episodes of the disease occur per year among African children,1,2 and roughly 1.2 million deaths (representing 2% of all premature deaths in the world) are caused annually by malaria in low- and middle-income countries,3 although estimates range from 700 000 to 2.7 million deaths per year.4 Of all global deaths due to malaria, around 75% are estimated to occur in African children.4

Current WHO recommendations for malaria control in children in endemic areas rely on case management, use of insecticide-treated nets and vector control,5,6 none of which has proved fully efficacious for controlling the infection.711 Hence, there is a need to test new strategies that, combined with existing interventions, can effectively reduce the burden of malaria among children in endemic areas.5

The delivery of intermittent preventive treatment in infants (IPTi) during routine contacts through the Expanded Programme on Immunization (EPI)1214 is a promising malaria control strategy whose efficacy rates in the prevention of malaria episodes1521 range from 22.6%16 to 63.2%.18 Cost-effectiveness analysis, which provides information that is crucial for policy recommendations for malaria control at both the national and international levels, can help guide the optimal allocation of health sector resources.22,23 To provide this information, we carried out a cost-effectiveness analysis based on the results of two very similar IPTi trials, one of which was undertaken in Ifakara, the United Republic of Tanzania, and the other in Manhiça, Mozambique.16,18

Methods

Study area and population

The trials are described in more detail elsewhere.16,18 The Tanzanian trial was based in Ifakara town (Kilombero district), whose population is 55 000. Malaria transmission is perennial, with two rainy seasons and a cool dry season from July to September. Sulfadoxine-pyrimethamine (SP) was the recommended first-line treatment for malaria during the study. Compliance with the routine EPI vaccination schedule was high, with 92% of children receiving three doses of diphtheria–tetanus–pertussis (DTP) vaccine plus oral poliovirus vaccine and 80% receiving measles vaccine. The rate of use of insecticide-treated nets was 70%.

The Mozambican study was based in Manhiça (Maputo province), a town of 36 000 inhabitants in southern Mozambique with a subtropical climate, a warm rainy season from November to April, and a cool, dry season the rest of the year. Compliance with EPI vaccines is very high, as more than 95% of children receive all three doses of the combination vaccine against DTP, polio and hepatitis B, and more than 85% are vaccinated against measles. In both sites malaria transmission is mostly due to Plasmodium falciparum. Insecticide-treated nets are not used in the community.

Cost-effectiveness analysis

The cost-effectiveness analysis presented here follows standard cost-effectiveness methods.2428 In cost-effectiveness analysis, the costs and outcomes of a new health intervention are compared with those of the currently practiced interventions and/or with doing nothing (no intervention). This enables the selection of competing interventions, based on their relative efficiency, to obtain better value for money in health spending and other benefits. To estimate the cost-effectiveness ratios of the IPTi intervention, the estimated aggregate effect of the IPTi intervention was divided by the estimated aggregate cost of providing the intervention for a reference target population of 1000 immunized infants. The cost-effectiveness ratios presented are incremental and reflect a comparison of the IPTi intervention with a do-nothing alternative. They include the cost per malaria episode averted, the cost per disability-adjusted life year (DALY) averted,2932 and the cost per malaria death averted. DALYs averted were calculated by combining the burden of disease averted due to less malaria morbidity (as a function of malaria incidence, disease duration and impact on quality of life) and less malaria mortality (as a function of malaria incidence, case-fatality rate and average life expectancy at age 1 year). Cost-effectiveness ratios are presented in United States dollars (US$) for the year 2006.

Estimation of health impact

The IPTi intervention evaluated in this analysis included the delivery of single doses of SP up to three times during the first year of life, alongside routine EPI vaccinations.

The health effects used in the cost-effectiveness analysis were based on the efficacy results from the Ifakara and Manhiça trials and on the incidence of malaria in these sites at the time of the trials.16,18 For the purposes of the economic evaluation, we used the total number of cases averted for a reference population of 1000 infants, based on the number of children enrolled in the trials who had received at least one dose of SP by 12 months of age. The trial results showed a reduction in the incidence of all malaria episodes of 63.2% (95% confidence interval, CI: 44.2–74.6) in Ifakara18 and 22.2% (95% CI: 3.9–37.0) in Manhiça.16 Neither study showed an increase in clinical episodes of malaria after discontinuation of IPTi (rebound effect).16,33 The malaria attack rates in the placebo group were 35.2% and 40.2% in the Ifakara and Manhiça trials, respectively. The cost-effectiveness ratio was also calculated using the pooled efficacy of the six completed IPTi trials that compared SP with placebo, which has been estimated at 30.1% (range: 19.7–39.1) against all clinical malaria episodes.34

Fewer malaria cases mean fewer malaria deaths. None of the IPTi trials conducted to date has been large enough to provide a direct estimate of the effect of the intervention on mortality. However, previous studies have shown that reducing malaria incidence does reduce mortality from the disease.35 Case-fatality field data derived from hospital admissions only have revealed case-fatality rates (CFRs) for malaria in infants ranging from 4.7%36 to 5.8%.37 A recent epidemiological model based on field data yielded a case-fatality rate for malaria in infants of 1.57%,38,39 and that is the rate we employed in this study. Because hospitalized infants are more likely to have severe malaria episodes, it was considered more appropriate to use the lower rate of 1.57% to reflect the CFR for clinical episodes of all types. DALYs were calculated according to standard methods, excluding age weighting.4042 For infant deaths, an average life expectancy of 51.35 years was used based on life tables for men and women in eastern Africa.43

Intervention costs

We calculated both the financial (budgetary) and the non-financial costs of the IPTi intervention, which together comprised its economic costs. Non-financial implications (opportunity costs) for resource use had to do, for instance, with the utilization of spare health system capacity or the switching of health resources from one use to another.

To calculate economic costs of the IPTi intervention, we took into account all costs involved in implementing it, including the costs of planning, delivery and monitoring. We also included all costs associated with policy change (strategy definition), sensitization (meetings with health sector stakeholders and district level health managers), behaviour change (communication to the population, staff training, intervention monitoring), the IPTi drug SP (import, purchase, storage and distribution), and drug administration (drug delivery, mothers’ education, and filling out the health card).

Intervention costs were partially collected from the two trials. However, as the conditions surrounding neither trial reflected actual practice in terms of IPTi delivery and costs incurred, intervention costs were taken instead from a more recent cost study that was part of an IPTi community effectiveness trial conducted from 2005 to 2008 in the southern United Republic of Tanzania (Mtwara and Lindi regions), where Ifakara is also situated.44 The cost data collected from the Mwara and Lindi regions exclude research and other costs that are usually involved in clinical trials. Hence, they reflect the real costs of IPTi delivery in routine clinical practice in the southern part of the country. Given the similarities between Mozambique and the United Republic of Tanzania in per capita incomes and health service delivery, including EPI schedule, the cost data collected in Mtwara and Lindi regions were also considered the most appropriate for application in the Manhiça study.44 Only the price of SP was treated as different between the two sites.

IPTi intervention costs are presented in Table 1, with financial and non-financial costs presented separately. In the United Republic of Tanzania, the cost per dose of IPTi delivered was roughly US$ 0.128. Of this amount, 60% comprised financial costs: US$ 0.0536 per dose for training, US$ 0.019 per dose for sensitization, and US$ 0.0136 per dose for purchase of the drug (including wastage). An average dose of half a tablet of SP and an assumed wastage rate of 30% were used to calculate the cost per dose, based on the price of the drug in 2006 in the Medical Stores Department (the agency responsible for bulk purchases of medicines and medical supplies) of the United Republic of Tanzania. In Mozambique the drug price used was US$ 0.0375 per dose, and as a result the total cost per dose delivered (US$ 0.1522) was higher in that country. As not all infants receiving the first dose receive the second and third doses, the IPTi intervention costs for the reference target of 1000 infants were adjusted for a drop-out rate of 4% from the first to the second dose in both sites, and of 19% and 15% from the second to the third dose for Ifakara and Manhiça, respectively. Hence, 77% of infants in Ifakara and 81% in Manhiça were presumed to receive three doses of SP.16,18

Table 1
Intervention costs per dose of SP delivered in Mozambique (Manhiça) and the United Republic of Tanzania (Ifakara) (2006 prices)

Sensitivity analysis

Multivariate sensitivity analysis was performed using Monte-Carlo simulations generated by @Risk (version 4.5) add-in tool to Microsoft Excel© (Palisade Corporation, Ithaca, NY, USA) to explore the robustness of the results in the face of simultaneous variation in selected assumptions and data inputs. Cost-effectiveness ranges were generated stochastically by varying four key input parameters – IPTi efficacy, case-fatality rate, malaria attack rate and cost per dose of IPTi delivered – in 10 000 simulations. The efficacy ranges were defined by the 95% CI from the trials themselves, while for the other three variables the 95% confidence ranges were assumed. The range distributions were assumed to be triangular.

Results

Table 2 shows health benefits and net intervention costs. Based on efficacy results from the two trial settings, the IPTi intervention resulted in 223 and 89 prevented episodes of malaria in Ifakara and in Manhiça, respectively, for every 1000 immunized infants. Assuming a case-fatality rate of 1.57%, the number of deaths averted per 1000 infants receiving the intervention was estimated at 3.5 in Ifakara and 1.4 in Manhiça. The number of DALYs averted was estimated at 118.9 per 1000 infants in Ifakara and 47.6 per 1000 infants in Manhiça. Intervention costs were estimated at US$ 422 per 1000 immunized infants in Manhiça and US$ 350 in Ifakara.

Table 2
Intervention costs, intervention efficacy and health benefits per 1000 infants receiving IPTi against malaria in Mozambique (Manhiça) and the United Republic of Tanzania (Ifakara), 2006

Cost-effectiveness ratios are presented in Table 3. Using efficacy data from the two trial sites, the costs estimated were as follows: per DALY averted, US$ 3.7 (range: 1.6–12.2) for Ifakara and US$ 11.2 (range: 3.6–92.0) for Manhiça; per malaria episode averted, US$ 1.6 (range: 0.8–4.0) for Ifakara and US$ 4.7 (range: 1.7–30.3) for Manhiça; and per death averted, US$ 100.2 (range: 43.0–330.9) for Ifakara and US$ 301.1 (range: 95.6–2498.4) for Manhiça.

Table 3
Cost-effectiveness of malaria IPTi in a study in Mozambique (Manhiça) and the United Republic of Tanzania (Ifakara), 2006

Table 3 also presents cost-effectiveness ratios using an efficacy rate of 30% from the pooled analysis including the six IPTi trials with SP.34 The costs estimated were as follows: per DALY averted, US$ 7.9 (range: 3.2–27.0) for Ifakara and US$ 8.3 (range: 3.3–27.5) for Manhiça; per malaria episode averted, US$ 3.3 (range: 1.4–10.3) for Ifakara and US$ 3.5 (range: 1.6–11.0) for Manhiça; per death averted, US$ 211.0 (range: 84.5–730.2) for Ifakara and US$ 222.8 (range: 88.6–747.1) for Manhiça.

Discussion

According to the cost-effectiveness analysis of IPTi, this strategy could be classified as highly cost-effective for controlling malaria in African infants. The cost per DALY averted was under US$ 12, and the cost per death averted was under US$ 310 in both study sites. Due to the higher efficacy reported in the Ifakara trial, cost-effectiveness ratios were more favourable in that study than in the one conducted in Manhiça. However, the reverse results were obtained when the pooled efficacy results were used.

IPTi offers an excellent value for the money when judged by a standard of under US$ 50 per DALY averted for a “very cost-effective intervention”.22 There are two further benefits of the IPTi intervention that are not reflected in these findings: anaemia prevention and cost savings. In past trials, the IPTi intervention (using SP) has been shown to reduce the incidence of anaemia by as much as 15.1% (95% CI: 6.3–23.1)34. Furthermore, the fewer the cases of malaria, the less treatment-seeking and the greater the cost savings, a fact not reflected in the cost-effectiveness ratios presented above. While care is not sought for all malaria cases, most receive some form of therapy, either in a public or private clinic, a traditional care setting, or as self-treatment. These additional cost savings to the health system make the intervention even more attractive for ministries of health of malaria-endemic countries. When savings to the patient are considered (in health-care costs, transportation costs, travel time and time spent ill, etc.), the intervention becomes more attractive for its beneficiaries as well.

This study is beset by several uncertainties. The multivariate sensitivity analysis yielded wide confidence intervals resulting from the ranges of four key input parameters. For example, the cost per DALY averted ranged from US$ 1.6 to US$ 12.2 in the United Republic of Tanzania and from US$ 3.6 to US$ 92.0 in Mozambique. However, these wide ranges were generated because a considerable degree of uncertainty in the selected parameters was allowed for, as shown in Table 4. Furthermore, even with an upper confidence limit of US$ 12.2 per DALY averted in the United Republic of Tanzania and an upper confidence limit of US$ 92.0 per DALY averted in Mozambique, IPTi is still an attractive health intervention. Counting only the financial cost of the IPTi intervention in Mozambique would reduce the upper confidence limit for the cost per DALY averted to US$ 61.

Table 4
Distribution of probability parameters in probabilistic sensitivity analysis from study of malaria IPTi, Mozambique (Manhiça) and the United Republic of Tanzania (Ifakara), 2006

A key uncertain variable – the case-fatality rate among infants – accounts for a significant share of the DALYs averted associated with malaria control interventions. For the multivariate analysis, a lower case-fatality rate of 1% was assumed If the case-fatality rate were in fact zero, the cost per DALY averted would be considerably higher at US$ 157.3 in the United Republic of Tanzania and US$ 472.7 in Mozambique. However, excluding such a potential health benefit from the cost-effectiveness calculation would underestimate the cost-effectiveness of the IPTi intervention, since in Africa malaria causes a considerable number of deaths in the target population of children less than 2 years of age. Furthermore, if mortality impact were excluded from this analysis, it would also need to be excluded from the evaluation of other malaria control interventions (see below).

Compared with other malaria control interventions targeting young children in Africa, IPTi appears to be among the most cost-effective. For example, a previous study reported a cost of US$ 10.3 per DALY averted for SP delivered weekly to infants between 2 and 12 months of age.36 A recent African continent-wide cost-effectiveness analysis using secondary data sources reported the following costs per DALY averted: case management with artemisinin-based combination therapy, US$ 10–12; insecticide-treated nets, US$ 29–40; and indoor residual spraying, US$ 32–41.45 In a review of malaria prevention strategies in childhood, the cost per DALY averted using insecticide-treated nets was found to be above US$ 9, including cost savings.23 Thus IPTi, at a cost of less than US$ 12 per DALY averted and with the likelihood of additional cost savings to the health system and patient, is found to be at least as cost-effective as other options for malaria control among infants.

From the health and cost-benefit points of view, IPTi merits serious consideration by health policy-makers, as it can have a major health impact in a vulnerable population, irrespective of the mortality impact of the intervention. Even if only the IPTi intervention costs are considered and potential cost savings are excluded, cost-effectiveness ratios are highly favourable and good value for money.

The Intermittent Preventive Treatment in Infants Consortium identified several issues, in addition to safety, efficacy and potential interactions between IPTi and EPI vaccines, which have been included in a portfolio of research to evaluate the potential of incorporating IPTi into malaria control strategies. Acceptability, immunological effects and impact on drug resistance are currently being investigated, although published models provide reassurance that IPTi is unlikely to have a dramatic effect on the spread of drug resistance.46,47

The difference between IPTi and intermittent preventive therapy in pregnancy (IPTp) should be understood by policy-makers, as these interventions do not directly compete with each other. While IPTi targets infants mainly to reduce malaria and anaemia among them, IPTp targets both mothers and infants and entails a broader set of health benefits for the infant, among them improved birth weight and fetal development, which result in significant long-term developmental gains. Hence, these strategies should, if possible, be implemented in parallel to attain optimal health benefits in these vulnerable populations.

In conclusion, the cost-effectiveness ratios of IPTi with SP are highly favourable in the two settings included in this study. These findings are likely to hold for other settings where IPTi is implemented provided a single-drug regimen is used for IPTi through the routine EPI schedule and malaria attack rates, IPTi efficacy rates and intervention costs resemble those evaluated in this study. Based on the cost-effectiveness of the intervention, it is recommended that IPTi with SP be implemented in malaria-endemic countries in sub-Saharan Africa as soon as possible, while ensuring that the intervention reaches the maximum number of infants through a routine contact point in the health system. ■

Acknowledgements

We are grateful to the members of the Intermittent Preventive Treatment in Infants Consortium for their input to this study and review of the paper. In particular we thank Andrea Egan and Elisa Sicuri (Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Spain) and Lesong Conteh (Swiss Tropical Institute, Basel, Switzerland). The authors thank the Bill and Melinda Gates Foundation for their funding to support the work of the IPTi Cost-Effectiveness Working Group.

Footnotes

Competing interests: None declared.

References

1. Korenromp E. Malaria incidence estimates at country level for the year 2004Geneva: World Health Organization: 2005.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005;434:214–7. doi: 10.1038/nature03342. [PMC free article] [PubMed] [Cross Ref]
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57. doi: 10.1016/S0140-6736(06)68770-9. [PubMed] [Cross Ref]
4. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg. 2001;64:1–11. [PubMed]
5. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what’s new, what’s needed: a summary. Am J Trop Med Hyg. 2004;71:1–15. [PubMed]
6. Breman JG, Mills A, Snow RW, Mulligan J-A, Lengeler C, Mendis KN, et al. Conquering malaria. In: Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D, et al, eds. Disease control priorities in developing countries2nd edition. New York: Oxford University Press: 2006. pp. 1-15.
7. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352:1565–77. doi: 10.1056/NEJMra043207. [PubMed] [Cross Ref]
8. Binka F, Akweongo P. Prevention of malaria using ITNs: potential for achieving the millennium development goals. Curr Mol Med. 2006;6:261–7. doi: 10.2174/156652406776055203. [PubMed] [Cross Ref]
9. Mabaso ML, Sharp B, Lengeler C. Historical review of malarial control in southern Africa with emphasis on the use of indoor residual house-spraying. Trop Med Int Health. 2004;9:846–56. doi: 10.1111/j.1365-3156.2004.01263.x. [PubMed] [Cross Ref]
10. Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol. 2005;50:53–70. doi: 10.1146/annurev.ento.50.071803.130439. [PubMed] [Cross Ref]
11. White GB. Malaria prevention by vector control: effectiveness of insecticidal methods. Parassitologia. 1999;41:385–7. [PubMed]
12. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health. 2005;10:815–7. doi: 10.1111/j.1365-3156.2005.01474.x. [PubMed] [Cross Ref]
13. O’Meara WP, Breman JG. Ellis McKenzie FE. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J. 2005;4:33–42. doi: 10.1186/1475-2875-4-33. [PMC free article] [PubMed] [Cross Ref]
14. Schellenberg D, Cisse B, Menendez C. The IPTi Consortium: research for policy and action. Trends Parasitol. 2006;22:296. doi: 10.1016/j.pt.2006.05.006. [PubMed] [Cross Ref]
15. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727–33. doi: 10.1136/bmj.331.7519.727. [PMC free article] [PubMed] [Cross Ref]
16. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis. 2006;194:276–85. doi: 10.1086/505431. [PubMed] [Cross Ref]
17. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, et al. Effect of intermittent treatment with amodiaquine on anaemia and malaria fevers in infants in Tanzania: a randomized, placebo-controlled trial. Lancet. 2003;361:1853–60. doi: 10.1016/S0140-6736(03)13504-0. [PubMed] [Cross Ref]
18. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomized, placebo-controlled trial. Lancet. 2001;357:1471–7. doi: 10.1016/S0140-6736(00)04643-2. [PubMed] [Cross Ref]
19. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dörnemann J, Pötschke M, et al. Intermittent preventive treatment in infants against malaria in Gabon - a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007;196:1595–602. doi: 10.1086/522160. [PubMed] [Cross Ref]
20. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson P, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis. 2007;45:16–25. doi: 10.1086/518575. [PubMed] [Cross Ref]
21. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, et al. Intermittence preventive treatment in infants as a means of malaria control: a randomized, double-blind, and placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother. 2007;51:3273–81. doi: 10.1128/AAC.00513-07. [PMC free article] [PubMed] [Cross Ref]
22. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354:378–85. doi: 10.1016/S0140-6736(99)02141-8. [PubMed] [Cross Ref]
23. Goodman CA, Mills AJ. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Plan. 1999;14:301–12. doi: 10.1093/heapol/14.4.301. [PubMed] [Cross Ref]
24. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275–83. [PMC free article] [PubMed]
25. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes2nd edn. Oxford: Oxford University Press; 1997.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicineNew York: Oxford University Press; 1996.
27. Luce B, Manning W, Siegel J, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicineNew York: Oxford University Press; 1996. pp. 82-134.
28. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations of the panel of cost-effectiveness in medicine. JAMA. 1996;276:1253–341. doi: 10.1001/jama.276.15.1253. [PubMed] [Cross Ref]
29. Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16:685–702. doi: 10.1016/S0167-6296(97)00005-2. [PubMed] [Cross Ref]
30. Murray CJ. Quantifying the burden of disease: the technical basis for disability adjusted life years. Bull World Health Organ. 1994;72:429–45. [PMC free article] [PubMed]
31. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy: Global Burden of Disease Study. Lancet. 1997;349:1347–52. doi: 10.1016/S0140-6736(96)07494-6. [PubMed] [Cross Ref]
32. Murray CJ, Lopez AD. Quantifying disability: data, methods and results. Bull World Health Organ. 1994;72:481–94. [PMC free article] [PubMed]
33. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomized, placebo-controlled trial. Lancet. 2005;365:1481–3. doi: 10.1016/S0140-6736(05)66418-5. [PubMed] [Cross Ref]
34. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. Intermittent preventive treatment for malaria control in African infants: Pooled analysis of safety and efficacy in six randomized controlled trials [submitted to LancetDec 2008].
35. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev. 2004:2. [PubMed]
36. Alonzo González M, Menéndez C, Font F, Kahigwa E, Kimario J, Mshinda H, et al. Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants. Bull World Health Organ. 2000;78:97–107. [PMC free article] [PubMed]
37. Schellenberg D, Menendez C, Aponte J, Guinovart C, Mshinda M, Tanner M, et al. The changing epidemiology of malaria in Ifakara Town, southern Tanzania. Trop Med Int Health. 2004;9:68–76. doi: 10.1046/j.1365-3156.2003.01161.x. [PubMed] [Cross Ref]
38. Ross A, Maire N, Molineaux L, Smith T. An epidemiological model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg. 2006;75:63–73. [PubMed]
39. Smith T, Ross A, Maire N, Rogier C, Trape J-F, Molineaux L. An epidemiological model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2006;75:56–62. [PubMed]
40. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–31. doi: 10.1093/heapol/16.3.326. [PubMed] [Cross Ref]
41. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Global burden of disease and risk factorsNew York: Oxford University Press; 2006.
42. Murray C, Lopez A. The global burden of disease. A comprehensive assessment of mortality and disability for diseases, injuries and risk factors in 1990 and projected to 2020Cambridge, MA: Harvard University Press; 1996.
43. Life tables for 191 countries for 2000: data, methods, resultsGeneva: World Health Organization; 2001 (GPE Discussion Paper 40).
44. Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso P, Mshinda H, et al. From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control. BMC Health Serv Res. 2008;8:165. doi: 10.1186/1472-6963-8-165. [PMC free article] [PubMed] [Cross Ref]
45. Morel CM, Lauer JA, Evans DB. Cost-effectiveness analysis of strategies to combat malaria in developing countries. BMJ. 2005;331:1299–304. doi: 10.1136/bmj.38639.702384.AE. [PMC free article] [PubMed] [Cross Ref]
46. Alexander N, Sutherland C, Roper C, Cisse B, Schellenberg D. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J. 2007;6:9. doi: 10.1186/1475-2875-6-9. [PMC free article] [PubMed] [Cross Ref]
47. O’Meara W, Smith DL, McKenzie FE. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med. 2006;3:e141. doi: 10.1371/journal.pmed.0030141. [PMC free article] [PubMed] [Cross Ref]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...